Search results for "Gamma-Aminobutyric Acid"

showing 10 items of 142 documents

Altered receptor subtypes in the forebrain of GABAA receptor δ subunit-deficient mice: recruitment of γ2 subunits

2002

A GABA(A) receptor delta subunit-deficient mouse line was created by homologous recombination in embryonic stem cells to investigate the role of the subunit in the brain GABA(A) receptors. High-affinity [(3)H]muscimol binding to GABA sites as studied by ligand autoradiography was reduced in various brain regions of delta(-/-) animals. [(3)H]Ro 15-4513 binding to benzodiazepine sites was increased in delta(-/-) animals, partly due to an increment of diazepam-insensitive receptors, indicating an augmented forebrain assembly of gamma 2 subunits with alpha 4 subunits. In the western blots of forebrain membranes of delta(-/-) animals, the level of gamma 2 subunit was increased and that of alpha …

MaleAzidesProtein subunitBiologyTritiumSynaptic TransmissionIon ChannelsGABAA-rho receptorInterleukin 10 receptor alpha subunitBenzodiazepinesMiceRadioligand Assaychemistry.chemical_compoundAnimalsReceptorGABA Agonistsgamma-Aminobutyric AcidMice KnockoutNeuronsBinding SitesMuscimolGABAA receptorGeneral NeuroscienceBrainAffinity LabelsNeural InhibitionReceptors GABA-AMolecular biologynervous systemMuscimolchemistryMutationForebrainFemaleCys-loop receptorsNeuroscience
researchProduct

Pregabalin as add-on treatment to botulinum toxin in idiopathic hemifacial spasm

2007

Botulinum toxin (BTX) is the medical therapy of choice in hemifacial spasm (HFS). However, in some patients, its therapeutic effect is insufficient. ### Patient 1. A 64-year-old man with a 10-year history of left-sided HFS was treated with BTX over a period of 6 years with good results. However, in the last 2 years the spasms were never sufficiently relieved by BTX. The patient felt significantly impaired, but declined to undergo neurosurgical intervention. The EDB test showed a decrease in the CMAP amplitude of 60%. Without changing the BTX regime, pregabalin (initially 75 mg/day increased every 5 days by 75 mg to 150 mg twice daily) was added for a 1-month trial period in the absence of a…

MaleBotulinum ToxinsPregabalinPregabalinPhysiology (medical)medicineHumansHemifacial SpasmAdverse effectgamma-Aminobutyric AcidAnti-Dyskinesia Agentsbusiness.industryTherapeutic effectMiddle Agedmedicine.diseaseBotulinum toxinSensory SystemsDiscontinuationDrug CombinationsTreatment OutcomeAdd on treatmentNeurologyAnesthesiaAnticonvulsantsFemaleNeurology (clinical)businessMedical therapymedicine.drugHemifacial spasmNeurology
researchProduct

CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

2003

Abnormally high spiking activity can damage neurons. Signaling systems to protect neurons from the consequences of abnormal discharge activity have been postulated. We generated conditional mutant mice that lack expression of the cannabinoid receptor type 1 in principal forebrain neurons but not in adjacent inhibitory interneurons. In mutant mice,the excitotoxin kainic acid (KA) induced excessive seizures in vivo. The threshold to KA-induced neuronal excitation in vitro was severely reduced in hippocampal pyramidal neurons of mutants. KA administration rapidly raised hippocampal levels of anandamide and induced protective mechanisms in wild-type principal hippocampal neurons. These protecti…

MaleCannabinoid receptorReceptors Drugmedicine.medical_treatment2-ArachidonoylglycerolExcitotoxicityHippocampal formationmedicine.disease_causeHippocampusMicechemistry.chemical_compoundPiperidinesCannabinoid receptor type 1Excitatory Amino Acid AgonistsReceptors Cannabinoidgamma-Aminobutyric AcidMice KnockoutNeuronsKainic AcidMultidisciplinaryBrainEndocannabinoid systemNeuroprotective AgentsMitogen-Activated Protein KinasesRimonabantSignal Transductionmedicine.medical_specialtyKainic acidPolyunsaturated AlkamidesGlutamic AcidMice TransgenicArachidonic AcidsIn Vitro TechniquesBiologyGlyceridesProsencephalonInternal medicinemedicineAnimalsFuransGenes Immediate-EarlyEpilepsyCannabinoidsBrain-Derived Neurotrophic FactorExcitatory Postsynaptic PotentialsMice Inbred C57BLEndocrinologyGene Expression Regulationnervous systemchemistryMutationPyrazolesCannabinoidNeuroscienceEndocannabinoidsScience
researchProduct

Inhibition by Anandamide and Synthetic Cannabimimetics of the Release of [3H]d-Aspartate and [3H]GABA from Synaptosomes Isolated from the Rat Hippoca…

2004

Cannabinoids (CB) can act as retrograde synaptic mediators of depolarization-induced suppression of inhibition or excitation in hippocampus. This mechanism may underlie the impairment of some cognitive processes produced by these compounds, including short-term memory formation in the hippocampus. In this study, we investigated several compounds known to interact with CB receptors, evaluating their effects on K +-evoked release of [ 3H]d-aspartate ([ 3H]d-ASP) and [ 3H]GABA from superfused synaptosomes isolated from the rat hippocampus. [ 3H]d-ASP and [ 3H]GABA release were inhibited to different degrees by the synthetic cannabinoids WIN 55,212-2; CP 55,940, and arachidonyl-2′- chloroethyla…

MaleCannabinoid receptorSettore BIO/14 - FARMACOLOGIAPolyunsaturated Alkamidesmedicine.medical_treatmentHippocampusArachidonic AcidsPharmacologyHippocampal formationDepolarization-induced suppression of inhibitionHippocampusBiochemistryCellular and Molecular Neurosciencechemistry.chemical_compoundglutamate releasemedicineAnimalsRats WistarCannabinoidgamma-Aminobutyric AcidCannabinoid Receptor AgonistsAspartic AcidCannabinoidsChemistryGeneral MedicineAnandamideCyclohexanolsgaba releaseEndocannabinoid systemRatsKineticsnervous systemBiochemistryAnimals Arachidonic Acids Aspartic Acid Calcium Cannabinoids Capsaicin Cyclohexanols gamma-Aminobutyric Acid Hippocampus Kinetics Polyunsaturated Alkamides Potassium Rats Receptors Cannabinoid SynaptosomesPotassiumCalciumlipids (amino acids peptides and proteins)CannabinoidCapsaicinCapsazepineEndocannabinoidsSynaptosomesNeurochemical Research
researchProduct

Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling.

2009

Cognitive impairment is one of the most important negative consequences associated with cannabis consumption. We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC). In addition, non-amnesic doses of either the mTOR blocker rapamycin or the protein synthesis inhibitor anisomycin abrogated the amnesic-like effects of THC, pointing to a mechanism involving new protein synthesis. Moreover, using pharmacological and genetic tools, we found that THC long-term memory deficits …

MaleCannabinoid receptormedicine.medical_treatmentGlutamic AcidHippocampusReceptors N-Methyl-D-AspartateGlutamatergicchemistry.chemical_compoundMiceCognitionReceptor Cannabinoid CB1Memorymental disordersmedicineAnimalsDronabinolPI3K/AKT/mTOR pathwayAnisomycingamma-Aminobutyric AcidMice KnockoutNeuronsProtein Synthesis InhibitorsSirolimusMemory DisordersChemistryGeneral NeuroscienceTOR Serine-Threonine KinasesRibosomal Protein S6 Kinases 70-kDanervous systemKnockout mouseNMDA receptorPhosphorylationCannabinoidNeuroscienceProtein KinasesAnisomycinCentral Nervous System AgentsSignal TransductionNature neuroscience
researchProduct

Interaction of uridine with GABA binding sites in cerebellar membranes of the rat

1983

The effect of uridine, a postulated anticonvulsant agent, on GABA receptors has been investigated. Uridine inhibits [3H]GABA binding to rat cerebellar buffer-washed membranes. Pretreatment of the membranes with Triton X-100 increases the effect of uridine on GABA-binding. The Scatchard analysis reveals that both high and low affinities of GABA for its receptors are affected by 1 mM uridine, while the apparent number of binding sites remains unchanged. The ability of uridine to interact competitively with GABA binding sites, also examined by the Lineweaver-Burk analysis, suggests a possible mechanism of action of this anticonvulsant agent, so including it among those compounds characterized …

MaleCerebellumReceptors Cell SurfaceBiologyBinding CompetitiveBiochemistrygamma-Aminobutyric acidCellular and Molecular Neurosciencechemistry.chemical_compoundGABA receptorCerebellummedicineAnimalsBinding siteReceptorUridinegamma-Aminobutyric AcidGABAA receptorCell MembraneRats Inbred StrainsGeneral MedicineReceptors GABA-AUridineRatsmedicine.anatomical_structurenervous systemBiochemistryMechanism of actionchemistryAnticonvulsantsmedicine.symptommedicine.drugNeurochemical Research
researchProduct

Effectiveness of Duloxetine Compared With Pregabalin and Gabapentin in Diabetic Peripheral Neuropathic Pain

2013

This study aimed to compare the effectiveness of duloxetine (DLX) and the anticonvulsants pregabalin (PGB) and gabapentin (GBP) for the treatment of diabetic peripheral neuropathic pain (DPNP) in routine clinical care.Data from a 6-month, noninterventional study involving 2575 patients in whom treatment of DPNP was initiated with or changed to DLX, PGB, or GBP (n=1523) were analyzed post hoc; patients treated with other medications or combinations were excluded from this analysis. Propensity scoring was used to compare patient groups, assessing Brief Pain Inventory (BPI), Clinical and Patient Global Impression (CGI/PGI), the Hospital Anxiety and Depression Scale (HADS), the Sheehan Disabili…

MaleCyclohexanecarboxylic AcidsGabapentinPregabalinPregabalinThiophenesDuloxetine HydrochlorideDuloxetine Hydrochloridechemistry.chemical_compoundDiabetic NeuropathiesGermanyHumansMedicineDuloxetineProspective StudiesAminesProspective cohort studygamma-Aminobutyric AcidAgedPain MeasurementAnalgesicsChi-Square Distributionbusiness.industryMiddle AgedHealth SurveysPeripheral neuropathic painTreatment OutcomeAnesthesiology and Pain MedicineMulticenter studychemistryAnesthesiaFemaleObservational studyNeurology (clinical)Gabapentinbusinessmedicine.drugThe Clinical Journal of Pain
researchProduct

Quantitation of GABA transporter 3 (GAT3) mRNA in rat brain by competitive RT-PCR.

1999

Gamma-amino butyric acid is the major inhibitory neurotransmitter in the brain. GABA transporters (GATs) remove GABA from the synaptic cleft. Till now, five distinct GABA transporters have been cloned and termed consecutively GAT1 to GAT4 and vGAT. To study the mechanisms by which tolerance and dependence associated with drugs enhancing GABAergic transmission is brought upon we analysed the mRNA expression levels of GATs in various brain regions under different conditions. In this paper, we describe our protocol for measurement of GAT3 mRNA expression, and its validation through control experiments for the various steps. We performed competitive reverse transcription and polymerase chain re…

MaleGABA Plasma Membrane Transport ProteinsDNA ComplementarySynaptic cleftBiologyBinding CompetitiveRibonucleasesAnimalsRNA MessengerReceptorgamma-Aminobutyric AcidGel electrophoresisBrain ChemistryMessenger RNAReverse Transcriptase Polymerase Chain ReactionGeneral NeuroscienceWild typeMembrane Transport ProteinsReproducibility of ResultsTransporterRats Inbred StrainsMolecular biologyReverse transcriptaseRatsReal-time polymerase chain reactionBiochemistryCarrier ProteinsBrain research. Brain research protocols
researchProduct

Anticonvulsant and antidepressant activity of the selected terpene GABA derivatives in experimental tests in mice

2006

The present study was designed to investigate the central nervous system activity of terpene GABA (and piracetam) derivatives designated as BF-1, BF-2, BF-3, BF-4, BF-5, BF-6. We assessed their anticonvulsant activity in the two main mouse models of seizures (MES-test, PTZ-test), an antidepressant-like effect in the forced swim test (FST), as well as an influence on spontaneous locomotor activity. Our study demonstrated the strong anticonvulsant activity of (1S,3R,7R)-(-)-3,8,8-trimethyl-4-aza-bicyclo[5.1.0]acetate-5-one hydrochloride (compound BF-2) in the PTZ-test. Activity of BF-2 was equipotent to ethosuximide (380 mg/kg, po) in the PTZ-test, when used at a dose of 100 mg/kg, po. No neu…

MaleGABAantidepressant-like activitymiceReceptors GABA-BAnimalsAnticonvulsantsMotor Activityanticonvulsant-Antidepressive AgentsSwimminggamma-Aminobutyric AcidterpenesPharmacological Reports
researchProduct

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of burning mouth syndrome : a randomized, double-blind, placebo contro…

2010

Burning Mouth Syndrome (BMS) is a disease that manifests as burning in the tongue or in any area of the oral mucosa, in the absence of clinically verifiable injuries. Objectives: To verify the efficacy of alpha lipoic acid (ALA) and gabapentin (GABA), used individually and jointly, to reduce the burning in patients with burning mouth and establish a drug therapy for the BMS. Study Design: During April and May 2008, we conducted a randomized, double-blind, placebo-controlled trial in the Department of Clinical Stomatology, Faculty of Dentistry, Rosario, Argentina. The gathering of patients was between those ones with BMS who were treated in our service between March 2003 and March 2008 witho…

MaleGabapentinCyclohexanecarboxylic AcidsPlacebo-controlled studyBurning Mouth SyndromePlaceboGroup BPharmacotherapyDouble-Blind MethodTonguemedicineHumansOral mucosaAminesGeneral Dentistrygamma-Aminobutyric AcidThioctic Acidbusiness.industryBurning mouth syndromeMiddle AgedCalcium Channel Blockers:CIENCIAS MÉDICAS [UNESCO]medicine.anatomical_structureOtorhinolaryngologyAnesthesiaUNESCO::CIENCIAS MÉDICASSurgeryDrug Therapy CombinationFemalemedicine.symptomGabapentinbusinessmedicine.drug
researchProduct